High-Dose CICR-NAM
Small molecule
High-Dose CICR-NAM is one of 37 small molecule programs targeting Ulcerative Colitis. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
460 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Omvoh
Eli LillyPhase 3
Velsipity
PfizerPhase 3
Mesalazine
FerringPhase 3
Adtralza
LEO PharmaPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
JNJ-42756493
Johnson & JohnsonPhase 3
Simponi
Johnson & JohnsonPreclinical
Remicade
OOrganon and Co
Preclinical
Humira
CCelltrion
Preclinical
HMPL-004
HHutchison Medipharma Limited
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for High-Dose CICR-NAM. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]